Products - Arthritis | Topic

Showing 13 products

Date | Sort by Title

Status: In developmentRemove ‘Status: In development’ filter

Anakinra for treating active Stills disease [ID1463]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 June 2020
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
19 August 2020
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 September 2020
Osteoarthritis: care and management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 August 2021
Osteoarthritis - naproxcinod [ID417]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Osteoarthritis - diacerein [ID332]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed [ID2710]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Magnetic resonance therapy for knee osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC

Arthritis Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 13 products

Anakinra for treating active Stills disease [ID1463]

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Osteoarthritis: care and management (update)

Osteoarthritis - naproxcinod [ID417]

Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]

Osteoarthritis - diacerein [ID332]

Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed [ID2710]

Magnetic resonance therapy for knee osteoarthritis

Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)

Arthritis Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 13 products

Status
1 selected